Data demonstrate proprietary X-Editors engineered using Scribe’s CRISPR by Design™ approach are a promising gene editing platform for developing genetic medicines with high activity, specificity and ...
ALAMEDA, Calif.--(BUSINESS WIRE)-- Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced its participation in the ...
Company will highlight developments enabled by its CRISPR by Design™ approach to engineer novel in vivo genetic medicines, including for ophthalmic diseases ALAMEDA, Calif.--(BUSINESS WIRE)--Scribe ...
Benjamin L. Oakes, PhD, Scribe Therapeutics co-founder, president, and CEO Scribe Therapeutics will partner with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly, to develop in vivo CRISPR ...
Scribe Therapeutics Co-Founder, President and CEO Benjamin L. Oakes, PhD A year and a half into a collaboration with Biogen to develop CRISPR-based therapies, Scribe Therapeutics says the companies ...
Scribe Therapeutics is adding another $100 million to its coffers six months after unveiling a $20 million series A and a partnership with Biogen to work on gene editing treatments for amyotrophic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results